S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, Multicenter, Phase II study

Oncologist

Volumn 19, Issue 11, 2014, Pages 1133-1134

  Ge, Feijiao ^a   Xu, Nong ^b   Bai, Yuxian ^c   Ba, Y ^d   Zhang, Yanqiao ^c   Li, Fei ^e   Xu, Huayan ^a   Jia, R ^a   Wang, Yan ^a   Lin, L ^a   Xu, Jianming ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 84908504263     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0223     Document Type: Article

References (1)

1. Jason E. Faris, Lawrence S. Blaszkowsky, Shaunagh McDermott et al. FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience. The Oncologist 2013;18:543-548.